



COMPANY OVERVIEW

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing REL-1017 (dextromethadone) in multiple indications. RELM-1017 is in Phase 2 for treatment resistant depression and preclinical testing for additional indications. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs.

RECENT NEWS

[Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®](#)

Jul 13 2020, 8:30 AM EDT

STOCK OVERVIEW

Symbol	RLMD
Exchange	Nasdaq
Market Cap	607.95m
Last Price	\$37.94
52-Week Range	\$9.60 - \$54.00

09/21/2020 04:00 PM EDT

INVESTOR RELATIONS

Relmada Therapeutics, Inc.
Sergio Traversa
880 Third Avenue
12th Floor
New York, NY 10022
T: 646-876-3459
straversa@relmada.com

MANAGEMENT TEAM

Sergio Traversa
Chief Executive Officer

Maged Shenouda
Chief Financial Officer

Thomas Wessel
Executive Vice President, Head of
Research and Development

Charles S. Ence
Chief Accounting and Compliance Officer

Molly Harper
Executive Vice President of Operations

Gina DiGuglielmo
Vice President and Head of Clinical
Operations

RELMADA THERAPEUTICS, INC.

880 Third Avenue
12th Floor
New York, NY 10022
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.